PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16087880-0	2005	Epithelial membrane protein-1 is a biomarker of gefitinib resistance.	Gefitinib	48-57	epithelial membrane protein 1	Homo sapiens	0-29	
16087880-1	2005	We describe a molecular resistance biomarker to gefitinib, epithelial membrane protein-1 (EMP-1).	Gefitinib	48-57	epithelial membrane protein 1	Homo sapiens	59-88	
16087880-1	2005	We describe a molecular resistance biomarker to gefitinib, epithelial membrane protein-1 (EMP-1).	Gefitinib	48-57	epithelial membrane protein 1	Homo sapiens	90-95	
16087880-2	2005	Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.	Gefitinib	0-9	epidermal growth factor receptor	Homo sapiens	82-94	
16087880-2	2005	Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.	Gefitinib	0-9	epidermal growth factor receptor	Homo sapiens	96-100	
16087880-2	2005	Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.	Adenosine Triphosphate	62-65	epidermal growth factor receptor	Homo sapiens	82-94	
16087880-2	2005	Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.	Adenosine Triphosphate	62-65	epidermal growth factor receptor	Homo sapiens	96-100	
16087880-3	2005	Treatment with gefitinib has resulted in clinical benefit in patients, and, recently, heterozygous somatic mutations within the EGFR catalytic domain have been identified as a clinical correlate to objective response to gefitinib.	Gefitinib	220-229	epidermal growth factor receptor	Homo sapiens	128-132	
16087880-7	2005	EMP-1 was identified as a surface biomarker whose expression correlated with acquisition of gefitinib resistance.	Gefitinib	92-101	epithelial membrane protein 1	Homo sapiens	0-5	
16087880-8	2005	EMP-1 expression was further correlated with lack of complete or partial response to gefitinib in lung cancer patient samples as well as clinical progression to secondary gefitinib resistance.	Gefitinib	85-94	epithelial membrane protein 1	Homo sapiens	0-5	
16087880-8	2005	EMP-1 expression was further correlated with lack of complete or partial response to gefitinib in lung cancer patient samples as well as clinical progression to secondary gefitinib resistance.	Gefitinib	171-180	epithelial membrane protein 1	Homo sapiens	0-5	
16087880-10	2005	This report suggests the role of the adhesion molecule, EMP-1, as a biomarker of gefitinib clinical resistance, and further suggests a probable cross-talk between this molecule and the EGFR signaling pathway.	Gefitinib	81-90	epithelial membrane protein 1	Homo sapiens	56-61	
16087880-10	2005	This report suggests the role of the adhesion molecule, EMP-1, as a biomarker of gefitinib clinical resistance, and further suggests a probable cross-talk between this molecule and the EGFR signaling pathway.	Gefitinib	81-90	epidermal growth factor receptor	Homo sapiens	185-189